Obesity rates have almost tripled since 1975, which researchers say is due to a combination of factors, including: Increased access to energy-dense food coupled with reduced physical activity Sleep deprivation Circadian desynchronization Chronic stress A rise in the use of certain medications known to result in weight gain, including some anti-epileptic and psychotropic drugs Other genetic and environmental factors As a result, prescription drug companies have sought their own way to target the treatment of obesity
It requires consistency between batches, controlled handling, verifiable analytical data, and sourcing discipline
Clinicians should emphasize overall health improvements rather than focusing solely on weight changes
both semaglutide and tirzepatide are off the FDA shortage list
But the results we have so far are impressive (more on that below!)
Advertisement Liraglutide studies Two large prospective outcomes studies afforded the opportunity to assess whether there was an association between a GLP-1 receptor agonist and pancreatitis